Table 3.

Dose-response associations between post-diagnosis statin use and cancer specific and all-cause mortality for HCC patients

Post-diagnosis statin use	Number of Patients	Number of Deaths	Person-Years	Mortality rate (95% CI) (per 100 person-years)	Unadjusted HR (95% CI)	Adjusted HR (95% CI)*
Cancer specific mortality
Statin non-user	13129	5460	22418.09	24.36 (23.72–25.01)	1.00 (Ref)	1.00 (Ref)
Low-dose statin use	1419	399	4069.91	9.08 (8.89–10.81)	0.46 (0.41–0.50)	0.47 (0.42,0.52)
High-dose statin use	874	249	2192.46	11.35 (10.04–12.86)	0.50 (0.44–0.57)	0.48 (0.42,0.56)
All-cause mortality
Statin non-user	13129	10686	22418.09	47.67 (46.77–48.60)	1.00 (Ref)	1.00 (Ref)
Low-dose statin use	1419	924	4069.91	22.70 (21.29–24.22)	0.52 (0.48–0.55)	0.50 (0.47,0.54)
High-dose statin use	874	539	2192.46	24.58 (22.59–26.75)	0.54 (0.50–0.59)	0.51 (0.46,0.56)

CI, confidence interval HCC, Hepatocellular carcinoma; HR, hazard ratio.

^*Adjusted for age, sex, race, BMI, alcohol abuse, smoking status, HCV infection, HBV infection, cirrhosis, NAFLD, stage, MELD score, APRI, ascites, hepatic encephalopathy, varices, Deyo comorbidity score, treatment (surgery, TACE, systemic chemotherapy, other), ECOG performance status, pre-diagnosis statin use, and post-diagnosis aspirin/NSAID use (time-varying).High-dose was defined as mean daily dose ≥20 mg, low-dose as <20mg.